# Prokidney Corp.: overview PROK · Nasdaq · CIK 1850270 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/prok.md) · [Financials](/companies/prok/financials.md) · [Filings](/companies/prok/filings.md) · [Insiders](/companies/prok/insiders.md) Latest reported revenue: [$150.0k](/filings/0001193125-26-342373.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001193125-26-342373). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001193125-25-274303.md) | [0.1 d](/filings/0001193125-26-113881.md) | [0.2](/filings/0001193125-26-225841.md) | [0.2](/filings/0001193125-26-342373.md) | [0.2](/filings/0001193125-25-274303.md) | [0.2 d](/filings/0001193125-26-113881.md) | [0.2](/filings/0001193125-26-225841.md) | [0.2](/filings/0001193125-26-342373.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(67856.6%) d](/filings/0001193125-26-113881.md) | [(17994.8%)](/filings/0001193125-26-225841.md) | [(17967.9%)](/filings/0001193125-26-342373.md) | [(17759.9%)](/filings/0001193125-25-274303.md) | [(20164.9%) d](/filings/0001193125-26-113881.md) | [(19881.9%)](/filings/0001193125-26-225841.md) | [(32248.7%)](/filings/0001193125-26-342373.md) | | Net margin | % | not reported | [(27997.4%) d](/filings/0001193125-26-113881.md) | [(7275.7%)](/filings/0001193125-26-225841.md) | [(7489.6%)](/filings/0001193125-26-342373.md) | [(7589.4%)](/filings/0001193125-25-274303.md) | [(8547.1%) d](/filings/0001193125-26-113881.md) | [(8865.9%)](/filings/0001193125-26-225841.md) | [(18948.0%)](/filings/0001193125-26-342373.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(31.6) d](/filings/0001193125-25-274303.md) | [(49.7) d](/filings/0001193125-26-113881.md) | [(30.7)](/filings/0001193125-26-225841.md) | [(34.5) d](/filings/0001193125-26-342373.md) | [(31.8) d](/filings/0001193125-25-274303.md) | [(38.3) d](/filings/0001193125-26-113881.md) | [(45.5)](/filings/0001193125-26-225841.md) | [(44.2) d](/filings/0001193125-26-342373.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [0.0](/filings/0000950170-25-040483.md) | [0.0](/filings/0001193125-26-113881.md) | [0.1](/filings/0001193125-26-113881.md) | [0.9](/filings/0001193125-26-113881.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(241678.9%)](/filings/0001193125-26-113881.md) | [(18477.8%)](/filings/0001193125-26-113881.md) | | Net margin | % | not reported | not reported | not reported | [(80507.9%)](/filings/0001193125-26-113881.md) | [(7725.2%)](/filings/0001193125-26-113881.md) | | Diluted EPS | $ per share | not reported | [(0.23)](/filings/0000950170-23-010324.md) | not reported | not reported | not reported | | Free cash flow | $m | [(55.5)](/filings/0000950170-24-034946.md) | [(78.9)](/filings/0000950170-25-040483.md) | [(124)](/filings/0001193125-26-113881.md) | [(156)](/filings/0001193125-26-113881.md) | [(135)](/filings/0001193125-26-113881.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/prok/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $25.2m | 12,341,266 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $20.1m | 9,854,178 | | Added +898,211 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $10.6m | 5,197,227 | | Added +3,810,111 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.9m | 2,390,147 | | Added +1,159,738 | | [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $4.1m | 2,000,000 | | Unchanged | | [Hennion & Walsh Asset Management, Inc.](/funds/1861642.md) | 2026-06-30 | $3.8m | 1,847,749 | | Added +236,056 | | [Artia Global Partners LP](/funds/1937964.md) | 2026-06-30 | $3.7m | 1,806,939 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.4m | 1,175,257 | | Added +28,320 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $2.2m | 1,099,400 | | Reduced −151,394 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $2.2m | 1,054,705 | | Reduced −1,216,872 | ## Recent filings [All 389 filings](/companies/prok/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 17:15 ET | [8-K](/filings/0001193125-26-438071.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-438071 | | 2026-08-10 | 16:11 ET | [8-K](/filings/0001193125-26-342397.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342397 | | 2026-08-10 | 16:10 ET | [10-Q](/filings/0001193125-26-342373.md) | Quarterly report, period 2026-06-30 | 0001193125-26-342373 | | 2026-05-29 | 16:02 ET | [8-K](/filings/0001193125-26-248210.md) | 5.07 Shareholder vote results | 0001193125-26-248210 | | 2026-05-15 | 11:49 ET | [8-K](/filings/0001193125-26-225848.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-225848 | | 2026-05-15 | 11:47 ET | [10-Q](/filings/0001193125-26-225841.md) | Quarterly report, period 2026-03-31 | 0001193125-26-225841 | | 2026-04-30 | 16:24 ET | [SCHEDULE 13D/A](/filings/0001140361-26-018258.md) | Ownership report, active investor, amended | 0001140361-26-018258 | | 2026-04-17 | 16:05 ET | [DEF 14A](/filings/0001140361-26-015362.md) | Proxy statement, period 2026-05-28 | 0001140361-26-015362 | | 2026-03-18 | 16:03 ET | [8-K](/filings/0001193125-26-113893.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-113893 | | 2026-03-18 | 16:01 ET | [10-K](/filings/0001193125-26-113881.md) | Annual report, period 2025-12-31 | 0001193125-26-113881 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-113881.md), filed Mar 18, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/70cd4a04-c196-4703-b8f4-1f7f150ac8ff) ## About the filer - CIK: 1850270 - Tickers: PROK - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: E9 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:09 ET. No prices; not investment advice.